Log in

Relevant bibliographies by topics / On-board diagnostics II / Journal articles

To see the other types of publications on this topic, follow the link: On-board diagnostics II.

Journal articles on the topic 'On-board diagnostics II'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'On-board diagnostics II.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Sahana H S, Ms. "Onboard Vehicle Diagnosis Fault Monitoring System Using IoT for Electric Vehicle." INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH IN ENGINEERING AND MANAGEMENT 09, no. 05 (2025): 1–9. https://doi.org/10.55041/ijsrem47828.

Full text

Abstract:

Abstract— The paper proposes a user-friendly cloud-based data acquisition and analytics system for vehicle diagnostic monitoring in real time. The vehicle's condition is assessed using the Onboard diagnostics (OBD) framework and the report is sent to the mobile of the driver via wifi on detection of unsafe and anomalous events in real time. Vehicle parameter values are instantaneously uploaded to the server. The smartphone app also visualizes data from the sensor and also generates warnings in real time. Keywords: Internet of Vehicles, On-board diagnostics (OBD), Vehicle self-diagnosing system

APA, Harvard, Vancouver, ISO, and other styles

2

Dr, Porag Kalita PhD*1 &. Mr Alakesh Kalita2. "POWER TRAIN AND EMISSION CONTROLS IN PASSENGER VEHICLES: STUDY OF EXHAUST GAS RECIRCULATION ( EGR)." INTERNATIONAL JOURNAL OF ENGINEERING SCIENCES & RESEARCH TECHNOLOGY 7, no. 2 (2018): 258–71. https://doi.org/10.5281/zenodo.1173460.

Full text

Abstract:

The goal of the On Board Diagnostics is to alert the driver to the presence of a malfunction of the emission control system, and to identify the location of the problem in order to assist mechanics in properly performing repairs. In addition, the On Board Diagnostics ( OBD-II) system should illuminate the malfunction indicator light ( MIL) and store the trouble code in the computer memory for all malfunction that will contribute to increased HC emissions.    Therefore, the power train is controlled by the power train control module (PCM) computer to deliver the required torque to the

APA, Harvard, Vancouver, ISO, and other styles

3

NIKITIN, DMYTRO, and OLEKSANDR RYBITSKYI. "INTEGRATION OF OBD-II VEHICLE DIAGNOSTICS WITH FINITE STATE MACHINE SOFTWARE DESIGN." Herald of Khmelnytskyi National University. Technical sciences 349, no. 2 (2025): 293–300. https://doi.org/10.31891/2307-5732-2025-349-43.

Full text

Abstract:

This research presents an innovative approach to integrating On-Board Diagnostics II (OBD-II) vehicle diagnostic systems with finite state machine (FSM) software design methodologies. The study addresses the growing complexity of modern vehicle diagnostic systems and proposes a novel framework that combines real-time vehicle diagnostics with automated software control systems. By leveraging FSM-based architectures, this research seeks to enhance diagnostic accuracy, reduce false detections, and provide a scalable solution adaptable to various vehicle models and driving conditions. The integrat

APA, Harvard, Vancouver, ISO, and other styles

4

Grzesik, Norbert. "F-16 Virtual Cockpit: A Project on Computer-Aided Learning and the Application of Integrated Diagnostics: Part II." Solid State Phenomena 220-221 (January 2015): 200–206. http://dx.doi.org/10.4028/www.scientific.net/ssp.220-221.200.

Full text

Abstract:

Part II of the publication concerns the next module of the project on the virtual cockpit. It is a very useful and handy educational tool for young flying adepts and ground personnel who can improve their knowledge about F-16 on-board operations on avionics and armament systems. The students (pilots and technicians) can also get familiar with integrated on-board diagnostics subsystems. Moreover, the paper examines a possibility of analysing malfunctions and faults faced during flight and within the process of maintenance.

APA, Harvard, Vancouver, ISO, and other styles

5

Yousuf, Chilonga, and Mkandawire Mtende. "Vehicle health inspection with enhanced auto diagnostics and maintenance." i-manager's Journal on Mechanical Engineering 14, no. 1 (2024): 34. http://dx.doi.org/10.26634/jme.14.1.20758.

Full text

Abstract:

This paper provides a comprehensive and cost-effective solution for automotive health maintenance and diagnostics. The software performs checks and analyses of key vehicle parameters through the use of the OBD-II (On-Board Diagnostics-II) port on the car. The port has to be physically connected to an interface called the ELM327 Bluetooth or Wi-Fi module that connects to the Android device running the software through Bluetooth or Wi-Fi. On a successful connection, the user can use the software to check the status of electronic control units (ECUs) throughout the vehicle to point out malfunctio

APA, Harvard, Vancouver, ISO, and other styles

6

Bysani, Chaitanya, T. S. Rama Krishna Prasad, and Sridhar Chundi. "Raspberry Pi for Commercial Applications." INTERNATIONAL JOURNAL OF COMPUTERS & TECHNOLOGY 11, no. 2 (2013): 2250–55. http://dx.doi.org/10.24297/ijct.v11i2.1179.

Full text

Abstract:

The objective of this paper is to create a low cost commercial off the shelf data analyzer for improving automotive safety and design a user interface infotainment system by using Raspberry Pi.Â In this paper we propose Raspberry pi based application that monitor the vehicle ECUs through an OBD-II(On Board Diagnostics) interface, perform Diagnostics with DTCs (Diagnostics trouble codes). Infotainment system having functions such as audio and video playback, games, internet connectivity through either USB Wi-Fi dongles or USB Modems and dashboard camera operation. Raspberry Pi will transmit the

APA, Harvard, Vancouver, ISO, and other styles

7

Michailidis, Emmanouel T., Antigoni Panagiotopoulou, and Andreas Papadakis. "A Review of OBD-II-Based Machine Learning Applications for Sustainable, Efficient, Secure, and Safe Vehicle Driving." Sensors 25, no. 13 (2025): 4057. https://doi.org/10.3390/s25134057.

Full text

Abstract:

The On-Board Diagnostics II (OBD-II) system, driven by a wide range of embedded sensors, has revolutionized the automotive industry by enabling real-time monitoring of key vehicle parameters such as engine load, vehicle speed, throttle position, and diagnostic trouble codes. Concurrently, recent advancements in machine learning (ML) have further expanded the capabilities of OBD-II applications, unlocking advanced, intelligent, and data-centric functionalities that significantly surpass those of conventional methodologies. This paper presents a comprehensive investigation into ML-based applicat

APA, Harvard, Vancouver, ISO, and other styles

8

O, Savchuk, Morgal O, and Muliarchuk A. "Logical Methods Usage in Diagnostics of the Multi-agents Air-conditioning System." Artificial Intelligence 29, AI.2024.29(4) (2024): 242–55. https://doi.org/10.15407/jai2024.04.242.

Full text

Abstract:

The possibility of cooperative agents usage for the on-board air conditioning system research and diagnosis is considered. A logical model for type I and II faults searching is proposed. This work provides an opportunity to master the practical knowledge and skills the first and second types logical models building to obtaining a minimum test of performance and finding malfunctions and damages the place at complex information systems development, operation and maintenance the stages. An algorithm has been developed that combines the development a generalized I type logical model from the syste

APA, Harvard, Vancouver, ISO, and other styles

9

Ramai, Clarence, Veeresh Ramnarine, Shankar Ramharack, Sanjay Bahadoorsingh, and Chandrabhan Sharma. "Framework for Building Low-Cost OBD-II Data-Logging Systems for Battery Electric Vehicles." Vehicles 4, no. 4 (2022): 1209–22. http://dx.doi.org/10.3390/vehicles4040064.

Full text

Abstract:

With the electrification of transport (BEVs) and the growing benefits of smart vehicles, there is a need for a simple solution to perform real-time monitoring of the BEV and its battery for diagnostics and coordinated charging. The On-Board Diagnostics (OBD) system, originally designed for internal combustion engine cars (ICE), can be used to extract the necessary BEV data. This paper presents a developed framework for a low-cost solution to online monitoring of BEVs. A Raspberry Pi Zero W, along with other auxiliary components, was installed in two Hyundai Ioniq Battery Electric cars to commu

APA, Harvard, Vancouver, ISO, and other styles

10

Phophongviwat, Teeraphon, Piyawong Poopanya, and Kanchana Sivalertporn. "Quantitative Assessment of EV Energy Consumption: Applying Coast Down Testing to WLTP and EPA Protocols." World Electric Vehicle Journal 16, no. 7 (2025): 360. https://doi.org/10.3390/wevj16070360.

Full text

Abstract:

This study presents a comprehensive methodology for evaluating electric vehicle (EV) energy consumption by integrating coast down testing with standardized chassis dynamometer protocols under WLTP Class 3b and EPA driving cycles. Coast down tests were conducted to determine road load coefficients—critical for replicating real-world resistance profiles on a dynamometer. Energy usage data were measured using On-Board Diagnostics II (OBD-II) and dynamometer measurements to assess power flow from the battery to the wheels. The results reveal that OBD-II consistently recorded higher cumulative ener

APA, Harvard, Vancouver, ISO, and other styles

11

Durbin, Thomas D., and Joseph M. Norbeck. "The Effects of Repairs on Tailpipe Emissions for On-Board Diagnostics II-Equipped Vehicles with the Malfunction Indicator Light Illuminated." Journal of the Air & Waste Management Association 52, no. 9 (2002): 1054–63. http://dx.doi.org/10.1080/10473289.2002.10470847.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Thatipamula, Sai, Muhammad Aadil Khan, and Simona Onori. "On-Board Diagnostics for Li-Ion Batteries Using Electrochemical Impedance Spectroscopy (EIS)-Based Health Estimation Models." ECS Meeting Abstracts MA2024-01, no. 53 (2024): 2802. http://dx.doi.org/10.1149/ma2024-01532802mtgabs.

Full text

Abstract:

There exists a growing need for standardized On-Board Diagnostics (OBD) for electric vehicles [1] to provide accurate health metrics and guarantees to both consumers and manufacturers. Previous work has shown the powerful LIB capacity-based State-of-Health (SoH) estimation capability of Electrochemical Impedance Spectroscopy (EIS) measurements and data-driven models [2] [3]. Since EIS measurements are dependent not only on SoH but also State-of-Charge (SoC) and temperature [4], it is important that the measurements are conducted after the cell reaches an equilibrium, and that these other varia

APA, Harvard, Vancouver, ISO, and other styles

13

Lim, JoonHoo, Won Yoo, La Kim, You Lee, and Hyung Lee. "Augmentation of GNSS by Low-Cost MEMS IMU, OBD-II, and Digital Altimeter for Improved Positioning in Urban Area." Sensors 18, no. 11 (2018): 3830. http://dx.doi.org/10.3390/s18113830.

Full text

Abstract:

This paper proposes an efficient multi-sensor system to complement GNSS (Global Navigation Satellite System) for improved positioning in urban area. The proposed system augments GNSS by low-cost MEMS IMU (Micro Electro Mechanical Systems Inertial Measurement Unit), OBD (On-Board Diagnostics)-II, and digital altimeter modules. For improved availability of time synchronization in urban area, an adaptive synchronization method is proposed to combine the external PPS (Pulse Per Second) signal and the internal onboard clock. For improved positioning accuracy and availability, a 17-state Kalman filt

APA, Harvard, Vancouver, ISO, and other styles

14

Kumar Singh, Siddhanta, and Anand Sharma. "Revving up insights: machine learning-based classification of OBD II data and driving behavior analysis using g-force metrics." Bulletin of Electrical Engineering and Informatics 14, no. 3 (2025): 2188–97. https://doi.org/10.11591/eei.v14i3.9398.

Full text

Abstract:

This research work uses machine learning (ML) approaches to classify on-board diagnostics II (OBD II) data and g-force measures to provide a thorough analysis of driving behavior. The research paper effectively demonstrates the classification of driving behaviours using OBD II and g-force data. Driving behaviours are analyzed by using ML algorithms such as random forest (RF), AdaBoost, and K-nearest neighbors (KNN). The analysis goes beyond a summary by discussing how OBD II data, g-force metrics, and the algorithms interrelate to classify ten distinct driving behaviors (e.g., weaving, swervin

APA, Harvard, Vancouver, ISO, and other styles

15

Brana, Irene, Christophe Massard, Richard D. Baird, et al. "Basket of baskets (BoB): A modular, open label, phase II, multicenter study to evaluate targeted agents in molecularly selected populations with advanced solid tumors." Journal of Clinical Oncology 37, no. 15_suppl (2019): TPS3151. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.tps3151.

Full text

Abstract:

TPS3151 Background: Basket trials with targeted agents can show high response rates for tumors with specific molecular profiles, granting extension of the label of some drugs. In other cases, study results were disappointing, likely due to the rarity of molecular alterations, limits in trial design and the difficulties in applying molecular tumor profiling in the clinical setting. Methods: Basket of Baskets (BoB), NCT03767075, aims to bridge the gap between Academic Genomics and clinical applications (ready-to market multi-marker Companion Diagnostics) by providing a sustainable and adaptable

APA, Harvard, Vancouver, ISO, and other styles

16

Mancuso, S., F. Frassati, A. Bemporad, and D. Barghini. "Three-dimensional reconstruction of CME-driven shock–streamer interaction from radio and EUV observations: a different take on the diagnostics of coronal magnetic fields." Astronomy & Astrophysics 624 (April 2019): L2. http://dx.doi.org/10.1051/0004-6361/201935157.

Full text

Abstract:

On 2014 October 30, a band-splitted type II radio burst associated with a coronal mass ejection (CME) observed by the Atmospheric Imaging Assembly (AIA) on board the Solar Dynamic Observatory (SDO) occurred over the southeast limb of the Sun. The fast expansion in all directions of the plasma front acted as a piston and drove a spherical fast shock ahead of it, whose outward progression was traced by simultaneous images obtained with the Nançay Radioheliograph (NRH). The geometry of the CME/shock event was recovered through 3D modeling, given the absence of concomitant stereoscopic observation

APA, Harvard, Vancouver, ISO, and other styles

17

Monier, Richard. "The Behavior of Bp He-weak Stars in the Far-UV—Paper XII: HD 175156." Research Notes of the AAS 7, no. 8 (2023): 160. http://dx.doi.org/10.3847/2515-5172/acebd1.

Full text

Abstract:

Abstract The analysis of four spectra of the B5 He-variable star HD 175156 recorded by the SWP camera on board the International Ultraviolet Explorer reveals one possible instance of variations of the far-ultraviolet spectral energy distribution shortwards of 1700 Å in spectra separated by 5 yr. Spectra collected over 4 consecutive days with identical exposure times do not vary, which probably rules out the possibility that HD 175156 be a rotational variable. The modeling of the Space Telescope Imaging Spectrograph spectrum reveals the presence of interesting resonance or low lying transitions

APA, Harvard, Vancouver, ISO, and other styles

18

Mischak-Weissinger, Eva M., Jochen Metzger, Annika Krons, et al. "Prospective Evaluation of Proteomic Screening with An Agvhd-Specific Proteomic Pattern MS-17." Blood 114, no. 22 (2009): 2246. http://dx.doi.org/10.1182/blood.v114.22.2246.2246.

Full text

Abstract:

Abstract Abstract 2246 Poster Board II-223 Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for many hematologic malignancies or hematopoietic dysfunction syndromes in adults, but the application is still limited due to major complications, such as severe graft versus host disease (GvHD) and infectious complications. Diagnosis GvHD is based on clinical features and biopsies, a non-invasive, unbiased laboratory test using proteomics was published previously and evaluated in a multicenter setting (Weissinger et al., 2007). In order to maintain good qu

APA, Harvard, Vancouver, ISO, and other styles

19

Yen, Meng-Hua, Shang-Lin Tian, Yan-Ting Lin, Cheng-Wei Yang, and Chi-Chun Chen. "Combining a Universal OBD-II Module with Deep Learning to Develop an Eco-Driving Analysis System." Applied Sciences 11, no. 10 (2021): 4481. http://dx.doi.org/10.3390/app11104481.

Full text

Abstract:

Vehicle technology development drives economic development but also causes severe mobile pollution sources. Eco-driving is an effective driving strategy for solving air pollution and achieving driving safety. The on-board diagnostics II (OBD-II) module is a common monitoring tool used to acquire sensing data from in-vehicle electronic control units. However, different vehicle models use different controller area network (CAN) standards, resulting in communication difficulties; however, relevant literature has not discussed compatibility problems. The present study researched and developed the

APA, Harvard, Vancouver, ISO, and other styles

20

Rocha, David, Gil Teixeira, Emanuel Vieira, João Almeida, and Joaquim Ferreira. "A Modular In-Vehicle C-ITS Architecture for Sensor Data Collection, Vehicular Communications and Cloud Connectivity." Sensors 23, no. 3 (2023): 1724. http://dx.doi.org/10.3390/s23031724.

Full text

Abstract:

The growth of the automobile industry in recent decades and the overuse of personal vehicles have amplified problems directly related to road safety, such as the increase in traffic congestion and number of accidents, as well as the degradation of the quality of roads. At the same time, and with the contribution of climate change effects, dangerous weather events have become more common on road infrastructure. In this context, Cooperative Intelligent Transport Systems (C-ITS) and Internet of Things (IoT) solutions emerge to overcome the limitations of human and local sensory systems, through t

APA, Harvard, Vancouver, ISO, and other styles

21

Rosenberger, Nico, Nikolai Hoffmann, Alexander Mitscherlich, and Markus Lienkamp. "Holistic Approach for Automated Reverse Engineering of Unified Diagnostics Service Data." World Electric Vehicle Journal 16, no. 7 (2025): 384. https://doi.org/10.3390/wevj16070384.

Full text

Abstract:

Reverse engineering of internal vehicle communication is a crucial discipline in vehicle benchmarking. The process presents a time-consuming procedure associated with high manual effort. Car manufacturers use unique signal addresses and encodings for their internal data. Accessing this data requires either expensive tools suitable for the respective vehicles or experienced engineers who have developed individual approaches to identify specific signals. Access to the internal data enables reading the vehicle’s status, and thus, reducing the need for additional test equipment. This results in ve

APA, Harvard, Vancouver, ISO, and other styles

22

NICKBAKHSH, S., F. THORBURN, B. VON WISSMANN, J. McMENAMIN, R. N. GUNSON, and P. R. MURCIA. "Extensive multiplex PCR diagnostics reveal new insights into the epidemiology of viral respiratory infections." Epidemiology and Infection 144, no. 10 (2016): 2064–76. http://dx.doi.org/10.1017/s0950268816000339.

Full text

Abstract:

SUMMARYViral respiratory infections continue to pose a major global healthcare burden. At the community level, the co-circulation of respiratory viruses is common and yet studies generally focus on single aetiologies. We conducted the first comprehensive epidemiological analysis to encompass all major respiratory viruses in a single population. Using extensive multiplex PCR diagnostic data generated by the largest NHS board in Scotland, we analysed 44230 patient episodes of respiratory illness that were simultaneously tested for 11 virus groups between 2005 and 2013, spanning the 2009 influenz

APA, Harvard, Vancouver, ISO, and other styles

23

Bernal-Mizrachi, Leon, Ajay K. Nooka, Leonard Heffner, et al. "Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)." Blood 134, Supplement_1 (2019): 3188. http://dx.doi.org/10.1182/blood-2019-131223.

Full text

Abstract:

Introduction: Proteasome inhibitors (PI) and immunomodulatory drugs have become the backbone of therapy for multiple myeloma (MM). The oral boron-containing selective and reversible proteasome inhibitor ixazomib has shown to induce deep and durable responses (Kumar RK et la, Blood 2016. 128(20):2415-2422). Triplets containing ixazomib, has shown to be more efficacious than doublet regimens in the relapse setting (Moreau P, et al. N Engl J Med 2016. 374:1621-1634).However, to date, there is not companion diagnostics capable of predicting PI response. We have recently discovered that MM patients

APA, Harvard, Vancouver, ISO, and other styles

24

Bernal-Mizrachi, Leon, Craig E. Cole, Leonard Heffner, et al. "Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)." Blood 132, Supplement 1 (2018): 2011. http://dx.doi.org/10.1182/blood-2018-99-119337.

Full text

Abstract:

Abstract Introduction: Proteasome inhibitors (PI) and immunomodulatory drugs have become the backbone of therapy for multiple myeloma (MM). The oral boron-containing selective and reversible proteasome inhibitor ixazomib has shown to induce deep and durable responses (Kumar RK et la, Blood 2016. 128(20):2415-2422). Triplets containing ixazomib, has shown to be more efficacious than doublet regimens in the relapse setting (Moreau P, et al. N Engl J Med 2016. 374:1621-1634).However, to date there is not companion diagnostics capable of predicting PI response. We have recently discovered that MM

APA, Harvard, Vancouver, ISO, and other styles

25

Panina, Ekaterina, Steffen Koschmieder, Florian H. Heidel, et al. "Genomic Landscape and Molecular Risk in Patients with Advanced Myelofibrosis Treated within the Multicenter Phase Ib/II MPNSG0212 (POMINC) Trial." Blood 138, Supplement 1 (2021): 4637. http://dx.doi.org/10.1182/blood-2021-150361.

Full text

Abstract:

Abstract Introduction: Mutations (muts) in JAK2, MPL, and CALR are genetic hallmarks in myeloproliferative neoplasms such as myelofibrosis (MF). Prognostication in MF is predominantly based on clinical parameters according to the Dynamic International Prognostic Scoring System (DIPSS). However, gene mutations become increasingly important allowing for a more precised assessment of prognosis. For instance, CALR mutated MF is associated with favorable prognosis, while mutations in distinct high molecular-risk (HMR) genes are considered adverse. Our multicenter phase-Ib/II MPNSG-0212 trial (NCT01

APA, Harvard, Vancouver, ISO, and other styles

26

Lee, Juseong, Mihaela Mitici, Henk A. P. Blom, Pierre Bieber, and Floris Freeman. "Analyzing Emerging Challenges for Data-Driven Predictive Aircraft Maintenance Using Agent-Based Modeling and Hazard Identification." Aerospace 10, no. 2 (2023): 186. http://dx.doi.org/10.3390/aerospace10020186.

Full text

Abstract:

The increasing use of on-board sensor monitoring and data-driven algorithms has stimulated the recent shift to data-driven predictive maintenance for aircraft. This paper discusses emerging challenges for data-driven predictive aircraft maintenance. We identify new hazards associated with the introduction of data-driven technologies into aircraft maintenance using a structured brainstorming conducted with a panel of maintenance experts. This brainstorming is facilitated by a prior modeling of the aircraft maintenance process as an agent-based model. As a result, we identify 20 hazards associat

APA, Harvard, Vancouver, ISO, and other styles

27

Kadia, Tapan M., Gautam Borthakur, Koichi Takahashi, et al. "Phase II Study of CPX-351 Plus Venetoclax in Patients with Acute Myeloid Leukemia (AML)." Blood 136, Supplement 1 (2020): 20–22. http://dx.doi.org/10.1182/blood-2020-142074.

Full text

Abstract:

Background CPX-351 is a liposomal formulation of cytarabine (araC) and daunorubicin at a fixed molar ratio that is currently approved for the treatment of patients with therapy-related AML or secondary AML (s-AML) arising from prior myelodysplastic syndrome (MDS). Compared to 7+3, CPX-351 demonstrated higher response rates (ORR), better tolerability, and better survival (OS) in patients with s-AML. The OS benefit was also observed after stem cell transplant (SCT). The dose-finding study of CPX-351 in R/R AML demonstrated an ORR of 23%. Recently, addition of the BCL-2 inhibitor venetoclax (Ven)

APA, Harvard, Vancouver, ISO, and other styles

28

Irelli, Azzurra, Sofia Chiatamone Ranieri, Daniela Di Giacomo, et al. "Role of the Molecular Tumor Board for the Personalized Treatment of Patients with Metastatic Breast Cancer: A Focus on the State of the Art in Italy." Cancers 15, no. 6 (2023): 1727. http://dx.doi.org/10.3390/cancers15061727.

Full text

Abstract:

Molecular tumor boards (MTBs) are multidisciplinary groups that combine molecular and clinical data from cancer patients in order to formulate treatment recommendations for precision medicine. To date, there is insufficient data to support the use of singleplex or next-generation sequencing (NGS) technologies to select first-line therapy for patients with metastatic breast cancer (MBC), but considering the high number of level II alterations, according to the ESMO scale for clinical actionability of molecular targets (ESCAT), it is suggested to include patients in molecular screening programs

APA, Harvard, Vancouver, ISO, and other styles

29

Massaro, Alessandro, Sergio Selicato, and Angelo Galiano. "Predictive Maintenance of Bus Fleet by Intelligent Smart Electronic Board Implementing Artificial Intelligence." IoT 1, no. 2 (2020): 180–97. http://dx.doi.org/10.3390/iot1020012.

Full text

Abstract:

This paper is focused on the design and development of a smart and compact electronic control unit (ECU) for the monitoring of a bus fleet. The ECU system is able to extract all vehicle data by the on-board diagnostics-(ODB)-II and SAE J1939 standards. The integrated system Internet of Things (IoT) system, is interconnected in the cloud by an artificial intelligence engine implementing multilayer perceptron artificial neural network (MLP-ANN) and is able to predict maintenance of each vehicle by classifying the driver behavior. The key performance indicator (KPI) of the driver behavior has bee

APA, Harvard, Vancouver, ISO, and other styles

30

Stojkov, Kristina, Tobias Silzle, Georg Stussi, et al. "I-Care for MDS: Development of Guidelines-Based Indicators for Appropriate Care in Adult Patients with Myelodysplastic Syndromes." Blood 134, Supplement_1 (2019): 4752. http://dx.doi.org/10.1182/blood-2019-122285.

Full text

Abstract:

Introduction: The incidence and prevalence of patients with Myelodysplastic Syndromes (MDS) are continuously rising due to population ageing and diagnostic advances. Consequently, the appropriate use of health care resources and assessment of their impact on relevant outcomes are of growing interest. Several evidence-based guidelines and recommendations (G&Rs) have been published for adult MDS patients. However, publishing G&Rs does not necessarily translate into better quality of care. Several studies have shown that MDS patients are not always treated according to published G&Rs,

APA, Harvard, Vancouver, ISO, and other styles

31

Maiti, Abhishek, Courtney D. DiNardo, Farhad Ravandi, et al. "Venetoclax, FLT3 Inhibitor and Decitabine in FLT3mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial." Blood 136, Supplement 1 (2020): 53–55. http://dx.doi.org/10.1182/blood-2020-137822.

Full text

Abstract:

Background: FLT3 mut confers higher risk of relapse and inferior overall survival (OS) in acute myeloid leukemia (AML). FLT3 inhibitors (FLT3i) show synergism with venetoclax (VEN), and hypomethylating agents (HMA); and clinical studies have shown promising results with HMA+FLT3i, and VEN+FLT3i in FLT3mut AML. We report the results of the first combination of VEN+FLT3i+HMA from a prospective phase 2 study. Methods: We conducted a subgroup analysis of FLT3mut AML pts treated with 10-day decitabine and VEN (DEC10-VEN) on a phase 2 trial. Addition of FLT3i of clinician's choice was allowed. We en

APA, Harvard, Vancouver, ISO, and other styles

32

Desikan, Sai Prasad, Hagop Kantarjian, Courtney D. DiNardo, et al. "A Phase I/II Study of Sapacitabine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia." Blood 138, Supplement 1 (2021): 3419. http://dx.doi.org/10.1182/blood-2021-151605.

Full text

Abstract:

Abstract Background: Sapacitabine is a novel, orally bioavailable, cytosine nucleoside analogue with a unique mechanism that generates single-stranded DNA breaks which are converted into double-stranded DNA breaks resulting in cell death. Previous studies of sapacitabine alone and alternating with decitabine (DAC) have demonstrated activity in acute myeloid leukemia (AML). Preclinical studies have suggested synergy with the combination of sapacitabine and a BCL-2 inhibitor. We conducted a study investigating the combination of sapacitabine and venetoclax (VEN) as an entirely oral regimen for p

APA, Harvard, Vancouver, ISO, and other styles

33

Bernal-Mizrachi, Leon, Ajay K. Nooka, Leonard Heffner, et al. "Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)." Blood 138, Supplement 1 (2021): 2758. http://dx.doi.org/10.1182/blood-2021-153922.

Full text

Abstract:

Abstract Introduction: Proteasome inhibitors (PI) and immunomodulatory drugs have become the backbone of therapy for multiple myeloma (MM). The oral boron-containing selective and reversible proteasome inhibitor ixazomib has shown to induce deep and durable responses (Kumar RK et la, Blood 2016. 128(20):2415-2422). Triplets containing ixazomib, has shown to be more efficacious than doublet regimens in the relapse setting (Moreau P, et al. N Engl J Med 2016. 374:1621-1634).However, to date, there is not companion diagnostics capable of predicting PI response. We have recently discovered that MM

APA, Harvard, Vancouver, ISO, and other styles

34

Manasanch, Elisabet E., Sundar Jagannath, Hans C. Lee, et al. "A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)." Blood 134, Supplement_1 (2019): 3116. http://dx.doi.org/10.1182/blood-2019-123205.

Full text

Abstract:

Background High risk smoldering multiple myeloma (HRSMM), defined as having immunoparesis and at least 95% abnormal plasma cells/all plasma cells by advanced flow cytometry, has a risk of progression to multiple myeloma of about 75% after 5 years of diagnosis. These patient have no symptoms and current standard is to follow them without treatment. Isatuximab is an IgG1 monoclonal antibody that binds to CD38 highly expressed in myeloma cells. Isatuximab has activity as monotherapy (overall response rate (ORR) 35%), with lenalidomide/dexamethasone (ORR 56%) and pomalidomide/dexamethasone (ORR 62

APA, Harvard, Vancouver, ISO, and other styles

35

Tasken, Kjetil, Hege Russnes, Aslaug Helland, et al. "Prototype precision oncology learning ecosystem: Norwegian precision cancer medicine implementation initiative." Journal of Clinical Oncology 40, no. 16_suppl (2022): e13634-e13634. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e13634.

Full text

Abstract:

e13634 Background: Norway, a country with a publicly funded health care system, was in 2018-19 lagging behind with respect to implementation of precision cancer medicine (PCM). Methods: Our approach mid-2019 was very simple and set out three aims: i) To establish access to advanced molecular diagnostics to allow identification and stratification of cancer patients into clinical trials; ii) To increase the volume of clinical trials with a PCM approach to gain experience and build competence; and iii) In parallel work for implementation of PCM into standard of care. Results: In a trans-disciplin

APA, Harvard, Vancouver, ISO, and other styles

36

Yamashita, Rei-Jo, Hsiu-Hsen Yao, Hiroki Yamashita, and Lo Chi. "Developing a Driver Alert and Alarm System for High Quality Driving Supports." International Journal of Advanced Research in Engineering 3, no. 1 (2017): 16. http://dx.doi.org/10.24178/ijare.2017.3.1.16.

Full text

Abstract:

Abstract—Prevention and vigilance plays a key role in preventing threatening risks and potential dangers when one is driving. In other to achieve the goal of averting danger when driving, people need valid and up to date information about: driving behavior, driving environment and vehicle status. There are a lot of factors that needs to be considered in order to keep a driver safe. Drunk driving, blind spots, bad driving habits, fatigue driving, and vehicle status are all factors that needs to be taken into account if safety is to be improved. Driving comfortability greatly depends on vehicle’

APA, Harvard, Vancouver, ISO, and other styles

37

Gisslinger, Heinz, Veronika Buxhofer-Ausch, Josef Thaler, et al. "Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study Results." Blood 132, Supplement 1 (2018): 3030. http://dx.doi.org/10.1182/blood-2018-99-118584.

Full text

Abstract:

Abstract Background: Ropeginterferon alfa-2b (Ropeg) is a novel long-acting monopegylated IFN-alpha-2b. Due to reduced dosing frequencies, better tolerability and improved compliance, Ropeg may be a favorable treatment option for long-term therapy in patients with polycythemia vera (PV). Study design: PEGINVERA phase I/II (NCT: 2010-018768-18), a prospective, open-label, multicenter study, investigated the efficacy and safety of Ropeg for long-term treatment in 51 patients aged ≥18 years with a confirmed diagnosis of PV, regardless of prior cytoreductive therapy. Following ≥1 year of 2-weekly

APA, Harvard, Vancouver, ISO, and other styles

38

Hutchings, Martin, Fritz C. Offner, Francesc Bosch, et al. "Phase 1 Study of CD19 Targeted 4-1BBL Costimulatory Agonist to Enhance T Cell (Glofitamab Combination) or NK Cell Effector Function (Obinutuzumab Combination) in Relapsed/Refractory B Cell Lymphoma." Blood 136, Supplement 1 (2020): 16–17. http://dx.doi.org/10.1182/blood-2020-136571.

Full text

Abstract:

Background: Up to 50% of patients suffering from Non-Hodgkin`s lymphoma (NHL) become refractory to or relapse after treatment (M. Crump, Blood 2017). With this, the lack of curative outcomes for patients with both indolent and aggressive NHL subtypes remains an unmet medical need. The CD20 CD3 T cell bispecific antibody glofitamab induces specific T-cell activation and has demonstrated significant single agent activity in r/r NHL patients (NP30179 study, M. Dickinson, EHA 2020, Abstract S241). RO7227166, a CD19 targeted 4-1BBL (CD137) costimulatory agonist has shown synergistic anti-tumor acti

APA, Harvard, Vancouver, ISO, and other styles

39

Morita, Kiyomi, Guillermo Montalban Bravo, Koji Sasaki, et al. "Long-Term Follow up of a Phase II Study of Guadecitabine (SGI-110) in Patients with Higher-Risk Myelodysplastic Syndrome (MDS)." Blood 136, Supplement 1 (2020): 21–22. http://dx.doi.org/10.1182/blood-2020-140614.

Full text

Abstract:

Introduction: Guadecitabine (SGI-110) is a next-generation hypomethylating agent (HMA) not metabolized by cytidine deaminase, a common pathway of decitabine deactivation. A multicenter phase II study has shown the clinical activity of guadecitabine in patients (pts) with intermediate and high-risk MDS (Lancet Heme 2019). Here we present an update of a single center phase II study of guadecitabine for pts with previously untreated higher risk MDS. Methods: 100 pts with higher risk MDS or chronic myelomonocytic leukemia (CMML, IPSS INT-2 or high, or bone marrow [BM] blast ≥10%) were treated unde

APA, Harvard, Vancouver, ISO, and other styles

40

Loges, Sonja, Michael Heuser, Joerg Chromik, et al. "Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS." Blood 132, Supplement 1 (2018): 2672. http://dx.doi.org/10.1182/blood-2018-99-120380.

Full text

Abstract:

Abstract Background AXL has been established as an independent prognostic factor in AML. AXL also represents a novel immune checkpoint because it directly inhibits NK cells and suppresses antigen presentation by antigen-presenting cells. Bemcentinib is a first-in-class, selective, orally bioavailable, AXL kinase inhibitor which is being evaluated as a therapy for solid tumours and myeloid malignancies in multiple phase II clinical trials. Increased levels of the plasma soluble, shed form of the AXL receptor (sAXL) upon bemcentinib exposure have been found across the clinical trial programme. T

APA, Harvard, Vancouver, ISO, and other styles

41

Maiti, Abhishek, Elias Jabbour, Nitin Jain, et al. "Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial." Blood 136, Supplement 1 (2020): 36–39. http://dx.doi.org/10.1182/blood-2020-136873.

Full text

Abstract:

Background: Intensive chemotherapy has improved complete remission (CR) rates in T-ALL/LBL. However, long-term overall survival (OS) continues to be suboptimal at about 50%. Nelarabine (NEL) is active in relapsed/refractory T-ALL. PEG-asparaginase (PEG) containing regimens have demonstrated significant activity in the pediatric population (Dunsmore et al. COG AALL0434. J Clin Oncol. 2018 Abstr #10500). We hypothesized that incorporating NEL and PEG in the frontline setting may further improve outcomes in adult T-ALL/LBL (NCT00501826). We had previously reported on the addition of nelarabine to

APA, Harvard, Vancouver, ISO, and other styles

42

Short, Nicholas J., Hagop Kantarjian, Marina Konopleva, et al. "Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia." Blood 138, Supplement 1 (2021): 2298. http://dx.doi.org/10.1182/blood-2021-153795.

Full text

Abstract:

Abstract Background: Ponatinib and blinatumomab are both highly effective in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The combination of these two agents may lead to deep and durable responses, thereby reducing the need for both chemotherapy and allogeneic stem cell transplant (ASCT) in first remission. Methods: In this phase II study, adults with newly diagnosed (ND) Ph+ ALL, relapsed/refractory (R/R) Ph+ ALL, or chronic myeloid leukemia in lymphoid blast phase (CML-LBP) were eligible. Patients (pts) were required to have a performance status of ≤2, total bil

APA, Harvard, Vancouver, ISO, and other styles

43

Morita, Kiyomi, Hagop M. Kantarjian, Guillermo Montalban Bravo, et al. "A Phase II Study of Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS)." Blood 136, Supplement 1 (2020): 7–9. http://dx.doi.org/10.1182/blood-2020-142003.

Full text

Abstract:

Introduction: Expression of PD1 and PD-L1 in MDS patients (pts) is enhanced by treatment with hypomethylating agents (HMA). Pts who are treated with nivolumab (Nivo), an anti-PD1 antibody, are known to show the upregulation of CTLA-4, and conversely, pts who are treated with ipilimumab (Ipi), an anti-CTLA-4 antibody, are known to show the upregulation of PD1 (Garcia-Manero et al ASH 2016). We therefore hypothesized that combination of Nivo and Ipi with azacytidine (Aza) might provide significant efficacy in pts with MDS. Methods: This is part of a basket exploratory phase II trial for Nivo and

APA, Harvard, Vancouver, ISO, and other styles

44

Brodsky, Robert, Hubert Schrezenmeier, Petra Muus, et al. "A Global Registry of Patients with Paroxysmal Nocturnal Hemoglobinuria." Blood 114, no. 22 (2009): 3007. http://dx.doi.org/10.1182/blood.v114.22.3007.3007.

Full text

Abstract:

Abstract Abstract 3007 Poster Board II-983 Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal hematopoietic stem cell disease characterized by complement-mediated hemolysis which can lead to life-threatening complications including thrombosis, kidney disease, and pulmonary hypertension. The natural history of PNH is highly variable and has previously been captured by retrospective assessment. However, the clinical presentation and prognosis of the disease has changed with the increased awareness of PNH, the increased use of more sensitive diagnostic tests, and the availability of new t

APA, Harvard, Vancouver, ISO, and other styles

45

Abuasab, Tareq, Hagop Kantarjian, Guillermo Garcia-Manero, et al. "Phase II Study of Cladribine, Idarubicin, Cytarabine (CLIA) Plus Gilteritinib in Patients with FLT3 Mutated Acute Myeloid Leukemia (AML)." Blood 138, Supplement 1 (2021): 2330. http://dx.doi.org/10.1182/blood-2021-151648.

Full text

Abstract:

Abstract Background: Addition of the FLT3 inhibitor midostaurin to intensive chemotherapy is the standard of care for newly diagnosed FLT3-mutated AML. Gilteritinib is a 2nd generation FLT-3 inhibitor approved for patients with relapsed/refractory (R/R) FLT3-mutated AML. We studied the combination of gilteritinib with a higher-dose araC-based regimen of Cladribine, Idarubicin, Cytarabine (CLIA) in patients with FLT3-mutated AML. Methods: Patients aged 18-65 years, fit for intensive chemotherapy, with newly diagnosed FLT3-mutated AML were enrolled. Induction was: Cladribine 5 mg/m 2 IV on days

APA, Harvard, Vancouver, ISO, and other styles

46

Bazinet, Alexandre, Hagop Kantarjian, Gautam Borthakur, et al. "A Phase II Study of 5-Azacytidine (AZA) and Venetoclax As Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission." Blood 138, Supplement 1 (2021): 2326. http://dx.doi.org/10.1182/blood-2021-150573.

Full text

Abstract:

Abstract Background: While remission rates for newly diagnosed AML have improved significantly with modern therapies, relapse remains a major cause of treatment failure and death. Post remission maintenance therapy in AML seeks to delay/prevent relapse with the goal of improving survival. From a historical cohort, among patients who did not receive allogeneic stem cell transplantation (aHSCT) in first remission (CR1), the median relapse-free survival (RFS) was 10m, 8m, and 5.7m for those who had received intensive therapy, lower-intensity therapy, or those with detectable minimal residual dise

APA, Harvard, Vancouver, ISO, and other styles

47

Short, Nicholas J., Hagop M. Kantarjian, Farhad Ravandi, et al. "Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study." Blood 136, Supplement 1 (2020): 15–17. http://dx.doi.org/10.1182/blood-2020-138569.

Full text

Abstract:

Background: Inotuzumab ozogamicin (INO) and blinatumomab both improve overall survival (OS) in relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). Use of these effective monoclonal antibodies in the frontline setting may lead to deep and durable remissions in older adults with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell ALL. Methods: Patients (pts) ≥60 years of age with newly diagnosed Ph-negative pre-B-cell ALL, including pts who had received no more than 1 prior cycle of chemotherapy, were eligible. Pts were required to have a performance status of ≤3, total bi

APA, Harvard, Vancouver, ISO, and other styles

48

Santa, José, Ramon Sanchez-Iborra, Pablo Rodriguez-Rey, Luis Bernal-Escobedo, and Antonio Skarmeta. "LPWAN-Based Vehicular Monitoring Platform with a Generic IP Network Interface." Sensors 19, no. 2 (2019): 264. http://dx.doi.org/10.3390/s19020264.

Full text

Abstract:

Remote vehicle monitoring is a field that has recently attracted the attention of both academia and industry. With the dawn of the Internet of Things (IoT) paradigm, the possibilities for performing this task have multiplied, due to the emergence of low-cost and multi-purpose monitoring devices and the evolution of wireless transmission technologies. Low Power-Wide Area Network (LPWAN) encompasses a set of IoT communication technologies that are gaining momentum, due to their highly valued features regarding transmission distance and end-device energy consumption. For that reason, in this work

APA, Harvard, Vancouver, ISO, and other styles

49

Kadia, Tapan M., Gautam Borthakur, Naveen Pemmaraju, et al. "Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)." Blood 136, Supplement 1 (2020): 17–19. http://dx.doi.org/10.1182/blood-2020-142092.

Full text

Abstract:

Background Treatment of older patients with newly diagnosed AML has been limited by modest response rates with low-intensity therapy and higher levels of toxicity with intensive therapy. We previously reported on a low-intensity backbone of cladribine + LDAC (CLAD/LDAC) alternating with hypomethylating agent (HMA) for older patients with AML, yielding higher rates of CR and improved outcomes compared to HMAs alone. Recently, addition of the BCL-2 inhibitor venetoclax to HMAs was shown, in a randomized study, to improve survival over HMAs alone. We hypothesized that the addition of venetoclax t

APA, Harvard, Vancouver, ISO, and other styles

50

Sparis, P. D., P. Botsaris, A. Karkanis, and J. Tatsios. "Three-way catalyst assessment via outlet—inlet temperature measurements: Driving tests." Proceedings of the Institution of Mechanical Engineers, Part D: Journal of Automobile Engineering 211, no. 6 (1997): 445–54. http://dx.doi.org/10.1243/0954407971526579.

Full text

Abstract:

This paper presents and discusses experimental data obtained during driving tests simulating the test cycle, ECE 15, and relates exhaust gas levels of hydrocarbon (HC) and carbon monoxide (CO) to catalyst outlet—inlet temperature differences. It also presents the preliminary results from the operation of a microcontrolled on-board diagnostics (OBD) II catalyst efficiency assessment system based on a statistical analysis of the catalyst outlet—inlet temperature difference thermocouple signal. There are indications that this system performs satisfactorily after an adequate warm-up period, if a s

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!